Clinical trial
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With…
NCT00161707 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00161707 |
|---|---|
| Title | Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency |
| Official title | Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Collaborators | Arriva Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Alpha1-antitrypsin Deficiency |
| Intervention type | Drug |
| Interventions | Aerosolized, Recombinant Alpha 1-Antitrypsin |
| Enrollment | 40 |
| Start date | Jan 7, 2003 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Sep 13, 2005 |
| Last update posted | May 5, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: